Please login to the form below
JAK1 inhibitor
This page shows the latest JAK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck KGaA and Aqilion AB partner in potential €960m deal
This includes AQ280, a JAK1 small molecule inhibitor initially being assessed as a potential treatment for eosinophilic oesophagitis, an inflammatory disease of the oesophagus.
Latest news
-
NHS Scotland to offer Jyseleca for patients with moderate rheumatoid arthritis
The SMC’s approval of the once-daily, oral, JAK1 preferential inhibitor is specifically for adults who have previously been treated for moderate RA.
-
GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA
with myelofibrosis who were symptomatic and anaemic and had been previously treated with an FDA-approved Janus kinase (JAK) inhibitor. ... Momelotinib is a JAK1/2 inhibitor, which treats symptoms of the cancer, but also targets other pathways called
-
Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
The Regulus programme is working to develop a next-generation JAK1 inhibitor for eosinophilic oesophagitis. ... The Regulus programme is focused on developing a next-generation JAK1 inhibitor and Aqilion will start by testing, assessing and developing
-
Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
Cibinqo is a once-daily, oral Janus kinase 1 (JAK1) inhibitor used in adult patients living with moderate-to-severe atopic dermatitis who have not yet found relief in currently available
-
FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD
A decision on the JAK1/2 inhibitor is expected by 22 June 2021, Incyte said in a statement. ... However, the JAK inhibitor plus standard-of-care failed to prevent complications in this patient group in the RUXCOVID study.
More from news
Approximately 1 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... It will face competition mainly from generic statins and PCSK9
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... t the only oral JAK inhibitor developer with its eye on that particular prize.
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 825. Takeda (Respiratory). AstraZeneca. Acquisition - asset. AZ buys Takeda global respiratory business including PDE 4
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
